Table 2.
Comparisons on gene polymorphisms between control and cancer groups.
| Genotype | Control (Groups 1, 2) | Cancer (Groups 3, 4) | p | ||
|---|---|---|---|---|---|
| Enzyme Deficiency | 1-Healthy | 2-Chronic Disease | 3-Cancer | 4-Advanced | |
| (n = 4) | (n = 11) | (n = 5) | (n = 10) | ||
| MTHFR 677 | |||||
| 0 (CC) | 2 (50%) | 5 (45.4%) | 2 (40%) | 2 (20%) | 0.70 |
| 1 (CT) | 1 (25%) | 5 (45.4%) | 2 (40%) | 7 (70%) | |
| 2 (TT) | 1 (25%) | 1 (9.1%) | 1 (20%) | 1 (10%) | |
| MTHFR 1298 | |||||
| 0 (AA) | 2 (50%) | 7 (63.6%) | 4 (80%) | 7 (70%) | 0.82 |
| 1 (AC) | 2 (50%) | 4 (36.4%) | 1 (20%) | 2 (20%) | |
| 2 (CC) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (10%) | |
| MTR 2756 | |||||
| 0 (AA) | 2 (50%) | 7 (63.6%) | 4 (80%) | 3 (30%) | 0.40 |
| 1 (AG) | 2 (50%) | 2 (18.2%) | 1 (20%) | 6 (60%) | |
| 2 (GG) | 0 (0%) | 2 (18.2%) | 0 (0%) | 1 (10%) | |
| MTRR 66 | |||||
| 0 (AA) | 2 (66.7%) | 6 (54.5%) | 4 (40%) | 0.93 | |
| 1 (AG) | 0 (0%) | 3 (27.3%) | 1 (20%) | 4 (40%) | |
| 2 (GG) | 1 (33.3%) | 2 (18.2%) | 1 (20%) | 2 (20%) | |
| DHFR 19 | |||||
| 00 (++) | 1 (25%) | 5 (45.4%) | 0 (0%) | 3 (30%) | 0.69 |
| 01 (+−) | 2 (50%) | 4 (36.4%) | 2 (40%) | 4 (40%) | |
| 11 (−−) | 1 (25%) | 2 (18.2%) | 3 (60%) | 3 (30%) | |
| Total Mutation | |||||
| ≥4 | 1 (25%) | 4 (36.4%) | 1 (20%) | 8 (80%) | 0.077 |
| 3.25 ± 0.50 | 3.36 ± 1.57 | 2.20 ± 1.30 | 3.90 ± 1.45 | 0.16 | |
| (3–4) | (1–6) | (1–4) | (1–6) | ||
| Posthoc | <4 (p = 0.049) | ||||
Nonparametric test, Posthoc by Wilcoxon test. 4 groups: Inflammation status indicated by chronic health diseases (Group 2) or advanced cancer stage (Group 4). MTHFR: methylenetetrahydrofolate; MTR: methionine synthase; MTRR: methionine synthase reductase; DHFR: dihydrofolate reductase.